• Zeliha Tuncer, Ercan Kurar, and Tugçe Duran.
• From the Department of Medical Biology (Tuncer, Kurar), Meram Faculty of Medicine, Necmettin Erbakan University, from the Department of Medical Biology (Tuncer); and from the Department of Medical Genetics (Duran), Faculty of Medicine, KTO Karatay University, Konya, Turkey.
• Saudi Med J. 2024 Feb 1; 45 (2): 121127121-127.

ObjectivesTo evaluate belinostat's (PXD101) activity on MCF-7 breast cancer stem cells (CSCs) via Wnt, Notch, and Hedgehog.MethodsThis research study was carried out at the Department of Medical Biology, Necmettin Erbakan University, Konya, Turkey, from June 2017 to July 2019. The effect of PXD101 on MCF-7 cell viability was determined by cell proliferation kit (XTT). Following belinostat treatment, CD44+/CD24- MCF-7 CSCs were isolated by FACS. Ribonucleic acid isolation and copy-deoxyribonucleic acid synthesis were carried out using HEK-293 cells, MCF-7 cells, and MCF-7 CSCs. Expression changes of metastasis-related genes, Wnt, Hedgehog, Notch, and stem cell markers were analysed by quantitative polymerase chain reaction. The IC50 in MCF-7 cancer cells was 5 μM for 48 hours. The FACS analysis indicated that 2% of the MCF-7 cancer cells were CSCs. Following belinostat treatment, the MCF-7 cell count decreased by 44%, and the MCF-7 CD44+/CD24- CSC count decreased by 66%.ResultsBelinostat treatment reduced the expression of metastasis, Wnt, Notch, Hedgehog, and stem cell marker genes.ConclusionBelinostat has a potential effect on the differentiation and self-renewal of breast CSCs.Copyright: © Saudi Medical Journal.

21 keywords...

hide…